VCAM-1
From Wikipedia, the free encyclopedia
|
Vascular cell adhesion molecule 1
|
||||||||||||||
| PDB rendering based on 1ij9. | ||||||||||||||
| Available structures: 1ij9, 1vca, 1vsc | ||||||||||||||
| Identifiers | ||||||||||||||
| Symbol(s) | VCAM1; CD106; DKFZp779G2333; INCAM-100; MGC99561 | |||||||||||||
| External IDs | OMIM: 192225 MGI: 98926 HomoloGene: 838 | |||||||||||||
|
||||||||||||||
| RNA expression pattern | ||||||||||||||
| Orthologs | ||||||||||||||
| Human | Mouse | |||||||||||||
| Entrez | 7412 | 22329 | ||||||||||||
| Ensembl | ENSG00000162692 | ENSMUSG00000027962 | ||||||||||||
| Uniprot | P19320 | Q3TR98 | ||||||||||||
| Refseq | NM_001078 (mRNA) NP_001069 (protein) |
NM_011693 (mRNA) NP_035823 (protein) |
||||||||||||
| Location | Chr 1: 100.96 - 100.98 Mb | Chr 3: 116.1 - 116.12 Mb | ||||||||||||
| Pubmed search | [1] | [2] | ||||||||||||
Vascular cell adhesion molecule 1, also known as VCAM1, is a human gene.
This gene is a member of the Ig superfamily and encodes a cell surface sialoglycoprotein expressed by cytokine-activated endothelium. This type I membrane protein mediates leukocyte-endothelial cell adhesion and signal transduction, and may play a role in the development of artherosclerosis and rheumatoid arthritis. Two alternatively spliced transcripts encoding different isoforms have been described for this gene.[1]
VCAM-1 (vascular cell adhesion molecule-1), also known as CD106, is a molecule with a considerable role in the human immune system.
Contents |
[edit] Structure
VCAM-1 contains six or seven immunoglobulin domains, and is expressed on both large and small vessels only after the endothelial cells are stimulated by cytokines.
[edit] Function
VCAM-1 promotes the adhesion of lymphocytes, monocytes, eosinophils, and basophils. Interestingly, certain melanoma cells can use VCAM-1 to adhere to the endothelium, and VCAM-1 may participate in monocyte recruitment to atherosclerotic sites. As a result, VCAM-1 is a potential drug target.
Upregulation of VCAM-1 in endothelial cells by cytokines occurs as a result of increased gene transcription (e.g., in response to Tumor necrosis factor-alpha (TNF-α) and Interleukin-1, aka IL-1) and through stabilization of Messenger RNA (mRNA) (e.g., Interleukin-4, aka IL-4). The promoter region of the VCAM-1 gene contains functional tandem NF-kB (nuclear factor-kappa B) sites.
The sustained expression of VCAM-1 lasts over 24 hours. Primarily, VCAM-1 is an endothelial ligand for VLA-4 (Very Late Antigen-1 or α4β1) of the β1 subfamily of integrins, and for integrin α4β7. VCAM-1 expression has also been observed in other cell types (e.g., smooth muscle cells).
[edit] References
[edit] Further reading
- Yonekawa K, Harlan JM (2005). "Targeting leukocyte integrins in human diseases.". J. Leukoc. Biol. 77 (2): 129–40. doi:. PMID 15548573.
- Wu TC (2007). "The role of vascular cell adhesion molecule-1 in tumor immune evasion.". Cancer Res. 67 (13): 6003–6. doi:. PMID 17616653.
[edit] External links
|
|||||||||||||||||

